Halozyme diversifies in drug delivery with Surf Bio buy
Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.
Eikon prices its IPO, seeking to raise $318m
Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.
The quiet evolution taking place in paediatric imaging
In children, MRI is increasingly used for imaging of the central nervous system (CNS), chest, abdomen, pelvis and musculoskeletal tissue.
Engineering “smarter” cells, with Tim Lu
Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Book your tickets and join the PM Society for the 40th PM Aw...
Tickets are on sale for the 40th anniversary of the PM Awards
The Pharmaceutical Manufacturing and Packaging Congress (PHA...
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam
5th mRNA-Based Therapeutics Summit Europe
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
VuuAI and Amiculum partner to transform content engagement i...
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
10th Tumor Models Summit San Francisco
Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity